Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MiniPDX-guided adjuvant therapy in biliary tract cancer
NCT07156058Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Jan 2023
- Primary completion
- Aug 2025
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Open-label trial of capecitabine, gemcitabine, cisplatin, fluorouracil and oxaliplatin in biliary tract cancer (BTC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Started Jan 2023; status: recruiting.
02
Drugs
capecitabinegemcitabinecisplatinfluorouraciloxaliplatin
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT07156058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07156058.